This workshop will explore what is needed to ensure that introductory research and programs are strategically designed, user-centered, and appropriately resourced to support successful rollout of CAB PrEP.
Continue Reading
AFRICANS LEADING RESEARCH EFFORT TO CONTROL HIV AND COVID-19 IN AFRICA: INTEREST 2022
Sub-Saharan Africa is home to 25.3 million (67%) of the global total of 37.7 million people living with HIV infection (UNAIDS 2021). To control the epidemic in Africa, it is essential that solutions for Africa be generated and implemented in Africa.
Continue Reading
SHE DECIDES: SUPPORTING PrEP DECISION-MAKING AMONG ADOLESCENT GIRLS AND YOUNG WOMEN IN A MULTI-PRODUCT PrEP MARKET
As we move toward a multi-product HIV prevention market, adolescent girls and young women must be empowered to choose an HIV prevention product that meets their needs.
Continue Reading
TURNING HIV PREVENTION RESEARCH INTO REALITY FOR ADOLESCENT GIRLS AND YOUNG WOMEN IN AFRICA
With the dapivirine vaginal ring and injectable cabotegravir poised to join oral pre-exposure prophylaxis (PrEP) as safe, effective HIV prevention products, people seeking an HIV prevention method that works for them will soon have real choices.
Continue Reading
ENABLING CHOICE: FIVE WAYS MOSAIC WILL SUPPORT PrEP POLICYMAKING AND PROGRAMS
For Zimbabwe and other countries in eastern and southern Africa, the emergence of new forms of PrEP presents a remarkable opportunity to offer potential users a range of choices to better meet their HIV prevention needs.
Continue Reading
NOVEL HIV PREVENTION PRODUCTS: EXPANDING THE EVIDENCE FOR INTRODUCTION
When countries introduce novel HIV prevention products, such as the PrEP ring and injectable CAB PrEP, how will women decide which product to use, and what will influence those decisions?
Continue Reading
“THESE NEW PRODUCTS GIVE ME POWER AND CONTROL OVER MY LIFE AND HEALTH”: CELEBRATING CHOICE ON INTERNATIONAL WOMEN’S DAY
Today, we observe International Women’s Day, a day to celebrate the many achievements of women around the globe.
Continue Reading
“A PROJECT THAT REALLY WANTS TO KNOW US”: IMPLEMENTING A USER-CENTERED APPROACH TO PrEP PRODUCT INTRODUCTION
In the MOSAIC project, the end user—that is, the people who need and/or want to use biomedical HIV prevention (PrEP) products—is at the center of all that we do.
Continue Reading
WHAT’S NEXT FOR CAB PrEP?
In this webinar, we explore ongoing and completed research on CAB PrEP, learn about the recently released FDA guidance, and hear from a panel of implementers and policymakers on what is needed to advance introduction of this new HIV prevention product.
Continue Reading
WHAT IS MOSAIC? MAXIMIZING OPTIONS TO ADVANCE INFORMED CHOICE FOR HIV PREVENTION
When I was a medical student in the early 1990s, the only drug we had to treat HIV was azidothymidine (AZT). I remember the excitement when combination therapy was developed; we all embraced a new acronym: HAART – highly active antiretroviral therapy.
Continue Reading